# Identifying Factors Regulating Medium Spiny Neuron Differentiation or Maintenance as Therapeutic Targets for Huntington's Disease using Induced Pluripotent Stem Cells

> **NIH NIH R01** · BUCK INSTITUTE FOR RESEARCH ON AGING · 2024 · $809,186

## Abstract

Huntington’s disease (HD) is a fatal, dominantly inherited neurodegenerative disorder that primarily affects
neurons in the striatum and cortex. Studies have identified striatal developmental impairments in HD and
transcriptional pathways that are amenable to disease-modifying interventions. Our central hypothesis is that
HD MSNs manifest developmental alterations that cause their dysfunction, dedifferentiation and potentially
dysregulation with inappropriate neuronal markers for MSNs. We further hypothesize that these HD phenotypes
can be corrected by modulating MSN developmental transcription factors or via drugs that correct transcriptional
dysregulation. Specifically, the failure of HD MSNs to differentiate properly makes them more susceptible to
neurodegeneration. Therefore, we can use our newly discovered MSN transcription factors to rescue this HD
phenotype. The early developmental alterations in MSNs set the stage for developing HD symptoms later in
life. In support of this hypothesis: 1) the maturation or maintenance of medium spiny neurons (MSNs) is
dysregulated in human isogenic HD-iPSCs with corrected alleles; 2) that the developmental trajectory is distinct
and alters the DLX gene family, key MSN developmental transcription factors, as determined by bulk and
scRNAseq; 3) using bioinformatics, drugs can be identified that can be repurposed to rescue this altered
developmental trajectory; 4) the key developmental MSN transcription factor, Bcl11b (also known as Ctip2), is
also a key maintenance factor in the mature MSNs, as conditional and specific deletion in postnatal mouse
MSNs converts their transcriptome to one that mimics human and mouse HD gene expression and 5)
identification of novel TFs required for striatal compartmentation and striosome maturation may be potential HD
therapeutic targets. Therefore, the specific aims are: Specific Aim 1 will characterize the cellular,
developmental and functional deficits in human isogenic HD-MSNs derived from induced pluripotent stem cells,
and evaluate if predicted key TFs or drugs rescue HD phenotypes; Specific Aim 2 will characterize the cellular,
developmental and functional deficits in isogenic human HD-organoids (structural organization and diversity of
cells) and evaluate if predicted key TFs or drugs rescue HD phenotypes. Specific Aim 3 will determine if
overexpression of MSN TFs corrects abnormalities in the Q175 mouse model with focus on the striosomal
compartment. These studies will advance our understanding of how to model HD in striatal MSNs/organoids
and identify novel mechanistic pathways and therapeutic targets for HD.

## Key facts

- **NIH application ID:** 10905875
- **Project number:** 2R01NS100529-06A1
- **Recipient organization:** BUCK INSTITUTE FOR RESEARCH ON AGING
- **Principal Investigator:** Lisa M Ellerby
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $809,186
- **Award type:** 2
- **Project period:** 2016-09-30 → 2029-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10905875

## Citation

> US National Institutes of Health, RePORTER application 10905875, Identifying Factors Regulating Medium Spiny Neuron Differentiation or Maintenance as Therapeutic Targets for Huntington's Disease using Induced Pluripotent Stem Cells (2R01NS100529-06A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10905875. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*